Creates provisions relating to 340B drugs

HB 785 prohibits health insurers, pharmacy benefits managers, and their affiliates from discriminating against covered entities participating in the federal 340B drug-pricing program. It requires equal reimbursement rates for 340B drugs compared to non-340B drugs (based on federal standards), bans different terms/conditions for 340B providers, and prevents interference with patient access to 340B drugs. Contracts containing discriminatory provisions become void, and violations may result in civil penalties up to $5,000 per day. The bill directly affects hospitals, clinics, and pharmacies enrolled in the 340B program, ensuring they receive equitable treatment from insurers and pharmacy networks. It aligns with federal law but adds state-level enforcement mechanisms for compliance.